Bioinnovator Novozymes Upgrades to LABVANTAGE R5.2
LABVANTAGE has announced that Novozymes (OMX: NZYM B), globally renowned biotechnology company, upgrades its LABVANTAGE Laboratory Information Management System (LIMS) to improve quality management of their 700+ enzymes, biopharmaceuticals and microorganisms in 130 countries worldwide. This $1 million project will upgrade and further enhance the existing SAPPHIRE R4.4 to LABVANTAGE R5.2. This project will include the addition of the Reagents & Standards Management (RSM) and Advanced Storage & Logistics (ASL) modules.
“Behind our company motto ‘Rethinking Tomorrow’ is our mission on bioinnovation –changing the world by applying biotechnology,” affirms Henning Nielsen, Novozymes Director of Assay & Technology Development. “To achieve this, we continuously ensure that our work environment is optimal with the most updated, stable and reliable systems set in place.”
“When I consider how LABVANTAGE can partake in innovating sustainable solutions with a global giant such as Novozymes, I identify yet another driver that motivates this organization to continue improving on all aspects of our products, services and team,” says Jeff Ferguson, CEO of LABVANTAGE.
The original implementation of SAPPHIRE started in 2004, and the upgrade to R5.2 will allow Novozymes to take advantage of the new out-of-the-box enhancements and additional functionality provided by the RSM, ASL and LEC modules, thus reducing the need for heavy configuration and customization.